Avid Bioservices

CDMO · NASDAQ

Price unavailable right now.

No price history for this range.

CDMO analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Feb 15, 2025

Bull case

Avid Bioservices Inc. demonstrates strong growth potential due to ongoing capacity expansions that are expected to more than double its revenue-generating capabilities within the next three years. The company's existing facilities offer significant opportunities for expansion, which is anticipated to generate high incremental margins, supporting a projected double-digit revenue compound annual growth rate (CAGR) and meaningful EBITDA margin expansion. Additionally, improvements in bookings momentum contribute positively to the overall demand outlook, further solidifying Avid's revenue guidance for fiscal year 2025 and enhancing visibility into its longer-term growth prospects.

Bear case

Avid Bioservices is facing several fundamental challenges that contribute to a negative outlook on its stock. The company's recent revenue miss, coupled with higher-than-expected selling, general, and administrative expenses resulting in a shortfall in EBITDA, indicates a trend of operational difficulties, particularly in the contract development and manufacturing organization (CDMO) segment. Additionally, external factors such as potential customer insourcing, a pullback in biotech funding, and intense competition raise concerns about revenue stability and growth, threatening the company's long-term profitability.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.